CN1141183A - Compound Vernonia anthelmintica tablet for treating vitiligo - Google Patents
Compound Vernonia anthelmintica tablet for treating vitiligo Download PDFInfo
- Publication number
- CN1141183A CN1141183A CN 95113704 CN95113704A CN1141183A CN 1141183 A CN1141183 A CN 1141183A CN 95113704 CN95113704 CN 95113704 CN 95113704 A CN95113704 A CN 95113704A CN 1141183 A CN1141183 A CN 1141183A
- Authority
- CN
- China
- Prior art keywords
- radix
- tablet
- treatment
- fructus
- vernonia anthelmintica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The medicine for curing leukodermia-compound vernonia anthelmintica tablet is made up of the Chinese medicinal materials of vernonia anthelmintica, wolfberry fruit, psoralea seed, multi-flower knotweed root, eclipta, tribulus fruit, dried rehmannia root, salvia root, licorice root, trace elements and cupric sulfate as raw materials, and using magnesium stearate and 10% of starch gelatin paste as auxiliary materials. Its cure rate is 17.25%, apparent effectual rate is 48.25% and effective rate is 34.03%, and its total effective rate is 99.53%.
Description
The invention belongs to the medicinal preparation technical field of the product that contains raw material or fuzzy structure, specifically derive from plant.
Vitiligo is common a kind of dermatosis, and white macula appears in cardinal symptom skin, and white macula appears in the severe patient face, even a sheet of skin presents white macula, has a strong impact on beauty treatment.Treat leukodermic Chinese patent medicine clinically and mainly contain white erosion ball, this medication journey is very long, generally wants 3～10 courses of treatment, tens days at least, some months at most, it is very slow to increase melanin on the patient skin, after treatment after a while, pore can only occur on patient's the skin, can not be linked to be sheet, therapeutic effect is not remarkable, does not consolidate, and relapse rate is very high.Also have a kind of Chinese patent medicine vitiligo sheet, curative effect is very low, does not use clinically.
The objective of the invention is to overcome the shortcoming of said medicine, provide a kind of treatment vitiligo dermatosis evident in efficacy, consolidate, have no side effect, the tablet that adopts Chinese medicine to make.
For achieving the above object, the solution that the present invention adopts is: it comprises with Chinese medicine Fructus Psoraleae, Radix Polygoni Multiflori, Herba Ecliptae, Fructus Tribuli, Radix Rehmanniae, Radix Salviae Miltiorrhizae, Radix Glycyrrhizae is the extract produced of raw material and medium-height grass Caulis Vernoniae andersonii, medlar powder, and the Chinese medicinal tablet that is mixed and made into trace element copper sulfate, in its proportion of raw materials, each percentages of ingredients content is:
Caulis Vernoniae andersonii 11～25%
Fructus Lycii 1.5～10%
Fructus Psoraleae 9～24%
Radix Polygoni Multiflori 9～24%
Herba Ecliptae 9～24%
Fructus Tribuli 9～24%
Radix Rehmanniae 4.5～15%
Radix Salviae Miltiorrhizae 2.5～10%
Radix Glycyrrhizae 1.5～10%
Copper sulfate 0.002～0.005%
In proportioning of the present invention, also comprising with magnesium stearate, 10% starch gelatin slurry is that the degree of adjuvant, its each adjuvant is:
Magnesium stearate 0.21～0.25%
10% starch gelatin slurry 3～5%
Caulis Vernoniae andersonii in proportioning raw materials of the present invention, Fructus Psoraleae, Radix Polygoni Multiflori, Fructus Tribuli have can swash in vivo tryrosinase, quickens melanic formation and strengthens photosensitization, and Radix Salviae Miltiorrhizae, Radix Rehmanniae have blood circulation promoting and blood stasis dispelling, the effects such as increasing melanin of dispeling the wind.
The present invention tests through clinical observation, cure rate is 17.25%, obvious effective rate is 48.25%, effective percentage is 34.03%, total effective rate is 99.53%, after 30 days course of therapy, melanin appears in most patient skin white maculas, it has short treating period, instant effect, evident in efficacy, advantage such as relapse rate is low, can extensively promote the use of clinically.
The inventor has provided used raw material, adjuvant and the proportioning of first embodiment of the invention (is example with 100000 of production products of the present invention):
Caulis Vernoniae andersonii 28kg Fructus Lycii 7kg
Fructus Psoraleae 24kg Radix Polygoni Multiflori 24kg
Herba Ecliptae 24kg Fructus Tribuli 24kg
Radix Rehmanniae 16kg Radix Salviae Miltiorrhizae 7kg
Radix Glycyrrhizae 5kg sulphuric acid steel 0.007kg
The starch gelatin slurry 6kg of magnesium stearate 0.37kg 10%
Its preparation technology is:
1. get Fructus Psoraleae, Radix Polygoni Multiflori, Herba Ecliptae, Fructus Tribuli, Radix Rehmanniae, Radix Salviae Miltiorrhizae, Radix Glycyrrhizae and choose decontamination, weigh, clean fast, add 8 to 10 times of water gagings and decoct three times by the weight of proportioning, each 1.5 to 2 hours, filter, merge three times filtrate, be evaporated to into syrupy shape, dust, standby.Take by weighing the adjuvant magnesium stearate by proportioning, make 10% starch gelatin slurry.
2. get Caulis Vernoniae andersonii, Fructus Lycii, choose decontamination, cleaning, drying are fast weighed by proportioning, and pulverize separately becomes fine powder, mix, and granulate with 10% starch gelatin slurry, and 100 mesh sieves were pulverized in cold drying, and were standby.
3. get above two kinds of medicated powder, mix homogeneously is granulated with moistening 14 mesh sieves that pass through of 55% ethanol, and cold drying after 12 mesh sieve granulate, adds the magnesium stearate lubricant, tabletting.
4. packing by quality standard of the present invention after the assay was approved.
Invention has been gone into to provide used raw material, adjuvant and the proportioning thereof of second embodiment of the invention (is example with 100000 of production products of the present invention) and has been:
Caulis Vernoniae andersonii 36kg Fructus Lycii 8kg
Fructus Psoraleae 36k Radix Polygoni Multiflori 36kg
Herba Ecliptae 36kg Fructus Tribuli 36kg
Radix Rehmanniae 20kg Radix Salviae Miltiorrhizae 8kg
Radix Glycyrrhizae 5kg copper sulfate 0.011kg
The starch gelatin slurry 7kg of magnesium stearate 0.5kg 10%
Its preparation technology and first embodiment are identical.
The inventor adopts the leukodermic compound Vernonia anthelmintica tablet of treatment of first embodiment of the invention preparation to carry out the clinical observation test, treatment patients with vitiligo 429 examples, wherein male 244 examples, woman's 185 examples, the oldest 68 years old, minimum 4 years old, 20～40 years old patient's 276 examples, patient's 54 examples more than 40 years old.In patients with vitiligo 429 examples, the course of disease had 54 examples, the patient of the course of disease in 1～5 year that 126 examples are arranged in 1 year with interior patient, and the course of disease has 150 examples the patient more than 6～10 years, and the course of disease has 99 examples the patient more than 10 years, and test situation is as follows:
1. case is selected
(1) local single-shot type vitiligo: case 110 examples.Cardinal symptom be the skin lesion single-shot in any position of human body, white macula appears at any position of human body skin isolatedly.
(2) women's head-ornaments multiple types vitiligo: case 39 examples.Cardinal symptom be skin lesion in the women's head-ornaments different parts, white macula appears on people's the head-face skin symmetrically.
(3) whole body multiple types vitiligo: case 280 examples.Cardinal symptom be the skin lesion area more than 2%, majority is diffusion profile in the form of sheets, or is drop shape dense distribution, white macula appears at each position of human body whole body.
2. Therapeutic Method
The oral the present invention of 429 routine patients, each 5 of adult's consumption, three times on the one, 30 days is a course of treatment, drug withdrawal is 4 days between the course of treatment.The course of disease was taken medicine 3～5 courses of treatment with interior patient in 1 year, and the patient in 1～5 year takes medicine 5～10 courses of treatment, and the patient in 6～8 years takes medicine 10～15 courses of treatment, and the patient takes medicine 15～20 courses of treatment more than 10 years.
3. criterion of therapeutical effect
Recovery from illness: the pigment on the leukoderma recovers normal.
Produce effects: the rehabilitation area reaches more than 60% of white macula area on the leukoderma.
Effectively: the white macula area dwindles on the skin, occurs melanin granule in the white macula.
Invalid: white macula no change before and after treatment on the skin.
4. clinical observation test and result of the test
After patients with vitiligo was taken the present invention, the rehabilitation of skin surface melanin was divided into for three phases:
The melanin apparition: after patients with vitiligo was taken the present invention course of treatment, pigment was deepened around the white macula, or occurs the big melanin point of needle point in the white macula.
The melanin rise period: after patients with vitiligo was taken the present invention 2～3 courses of treatment, melanin was deepened around the white macula, and white macula contracts in gradually, and the melanin point in the white macula increases, and increases.
The melanin incorporating period: after patients with vitiligo was taken the present invention 3～5 courses of treatment, the melanin point in the white macula enlarged gradually, is fused into lamellar mutually, and lamellar is converged, and white macula disappears and rehabilitation.
Result of the test: 429 routine patients with vitiligo, take the present invention 3～5 courses of treatment after, 74 examples of fully recovering account for 17.25%; Produce effects 207 examples account for 48.25%; Effective 146 examples account for 34.03%; Invalid 2 examples account for 0.47%; Total effective rate is 99.53%.
Function of the present invention and purposes: the present invention has liver-kidney tonifying, expelling wind and activating blood flow stagnation resolvation, increases Strong human body immunity and promotion melanin pigmentation function are used for the treatment of leucoderma disease.
Usage of the present invention and consumption: be grown up took three times on the 1st, and each 5, children reduce by half, One month is a course for the treatment of, and the course for the treatment of, the interval was 4 days, generally took 3～5 courses for the treatment of, to the course of disease Long patient, but the course for the treatment of proper extension.
Taboo of the present invention: diet acid in the treatment phase, peppery irritable food.
Storage of the present invention: sealing, shady and cool dry place storage.
The term of validity of the present invention: 2 years.
Claims (1)
1, the leukodermic compound Vernonia anthelmintica tablet of a kind of treatment, it is characterized in that it comprises with Chinese medicine Fructus Psoraleae, Radix Polygoni Multiflori, Herba Ecliptae, Fructus Tribuli, Radix Rehmanniae, Radix Salviae Miltiorrhizae, Radix Glycyrrhizae is the extract produced of raw material and Chinese medicine anthelmintic speckle legendary bird with poisonous feathers chrysanthemum, medlar powder, and the Chinese medicinal tablet that is mixed and made into trace element copper sulfate, in its proportion of raw materials, each percentages of ingredients content is:
Caulis Vernoniae andersonii 11～25%
Fructus Lycii 1.5～10%
Fructus Psoraleae 9～24%
Radix Polygoni Multiflori 9～24%
Herba Ecliptae 9～24%
Fructus Tribuli 9～24%
Radix Rehmanniae 4.5～15%
Radix Salviae Miltiorrhizae 2.5～10%
Radix Glycyrrhizae 1.5～10%
Copper sulfate 0.002～0.005%
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95113704A CN1049146C (en) | 1995-07-21 | 1995-07-21 | Compound Vernonia anthelmintica tablet for treating vitiligo |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95113704A CN1049146C (en) | 1995-07-21 | 1995-07-21 | Compound Vernonia anthelmintica tablet for treating vitiligo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1141183A true CN1141183A (en) | 1997-01-29 |
| CN1049146C CN1049146C (en) | 2000-02-09 |
Family
ID=5080025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95113704A Expired - Fee Related CN1049146C (en) | 1995-07-21 | 1995-07-21 | Compound Vernonia anthelmintica tablet for treating vitiligo |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1049146C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325068C (en) * | 2004-12-17 | 2007-07-11 | 斯拉甫·艾白 | Use of insect-expelling saligna injection liquid for cough and gasp catabasis drug |
| US9339521B2 (en) | 2007-04-17 | 2016-05-17 | Bayer Consumer Care Ag | Use of vernonia extract |
| CN114796311A (en) * | 2021-01-27 | 2022-07-29 | 保定华仁白癜风医院 | Pill of vernonia amygdalina for eliminating leukosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060649C (en) * | 1992-12-12 | 2001-01-17 | 杜文超 | Medicine for curing vitiligo and preparation method thereof |
-
1995
- 1995-07-21 CN CN95113704A patent/CN1049146C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325068C (en) * | 2004-12-17 | 2007-07-11 | 斯拉甫·艾白 | Use of insect-expelling saligna injection liquid for cough and gasp catabasis drug |
| US9339521B2 (en) | 2007-04-17 | 2016-05-17 | Bayer Consumer Care Ag | Use of vernonia extract |
| CN114796311A (en) * | 2021-01-27 | 2022-07-29 | 保定华仁白癜风医院 | Pill of vernonia amygdalina for eliminating leukosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1049146C (en) | 2000-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1186070C (en) | Medicine composition for treating impotence and its prepn | |
| CN1047946C (en) | Preparation for treating senile diseases | |
| CN1224614A (en) | Medicine for preventing and curing cardiac and cerebral vascular diseases and its preparation | |
| CN1682982A (en) | A Chinese medicinal pill for treating chronic nephropathy and renal insufficiency | |
| CN1772194A (en) | Chinese herbal medicine prepn for strengthening kidney-Yang | |
| CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN1965953A (en) | Compound medicinal granule capable of tonifying kidney and replenishing qi and method for preparing same | |
| CN101053621A (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| CN1943704A (en) | A Chinese traditional medicinal composition and its preparation method | |
| CN102018852B (en) | Ginseng and coptis capsule for quenching thirsty and reducing blood sugar and preparation process | |
| CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
| CN1049146C (en) | Compound Vernonia anthelmintica tablet for treating vitiligo | |
| CN1319574C (en) | Medicine for treating constipation | |
| CN1048324A (en) | The manufacture method of stone-dissolving medicine " Rongshibao " | |
| CN1105557A (en) | Method for preparation of weight-loosing medicine and its products | |
| CN1127344C (en) | Oral pill for curing diabetes and its complication | |
| CN1116068C (en) | Medicine for treating ichthyosis and preparing process thereof | |
| CN1111054C (en) | Medicine for treating apoplexy and its preparing process | |
| CN1843437A (en) | Medicinal composition for treating insomnia and its preparing process | |
| CN1876148A (en) | A Chinese medicinal composition for replenishing kidney and strengthening bone and preparation method thereof | |
| CN1814125A (en) | Rehmannia-root preparation | |
| CN1289108C (en) | Chinese medicine preparation for treating senile dementia and preparation thereof | |
| CN1317007C (en) | Pearl detoxifying oral liquid and preparing method tehreof | |
| CN1226044C (en) | Oral liquid for relieving rheumatic pains and stopping itch, and its preparation method | |
| CN1060087C (en) | Traditional Chinese medicine extract tablet and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |